← Back to headlines
Lexicon Pharma and Novo Nordisk Begin Obesity Drug Study
Lexicon Pharma (LXRX) and Novo Nordisk (NVO) have initiated a Phase 1 study for their investigational obesity drug, LX9851. This collaboration marks an early stage in the drug's development.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
